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ABSTRACT
Objectives: To determine the most cost-effective screen-
ing policy for population-based mammography breast
cancer screening in Slovenia using probabilistic sensitivity
analysis.
Methods: A time-dependent Markov model for breast cancer
was constructed. General principles of cost-effectiveness
analysis with multiple strategies were used to compare the
costs and effects of 36 different screening policies. Using
probability distributions for model parameters, the true effect
of uncertainty across model input parameters on expected
costs and effects was explored. The results from probabilistic
simulation analysis are presented in a form of cost-
effectiveness acceptability curves with cost-effectiveness
acceptability frontier.
Results: With the presented analysis, it was shown that a
1-year screening interval in population breast cancer screening
would produce less beneﬁts at higher costs than less intensive
screening and that a 2-year interval would be cost-effective
only at high values of society’s willingness to pay per quality-
adjusted life-year (QALY). Therefore, the optimal screening
policy should be chosen among 3-year-interval policies.
Conclusions: Based on commonly quoted thresholds of soci-
ety’s willingness to pay per QALY of $50,000, the optimal
approach in the Slovenian population would be screening
women aged from 40 to 80 years every 3 years.
Keywords: breast cancer screening, cost-effectiveness
acceptability frontier, multiple CEAC, probabilistic
cost-effectiveness analysis.
Introduction
Breast cancer is the most common cancer in the female
population in Slovenia with around 100 newly diag-
nosed cases per 100,000 women in a year and it will
afﬂict 1 in 15 Slovenian women by the age of 75 years
[1]. The costs of this disease are high, in terms of both
decreased health-related quality of life and health-care
consumption. Currently, the most effective method for
preventing premature mortality and morbidity due to
breast cancer is through the increased use of screening
programs, which enable identifying and treating
breast cancer at earlier stages. Beneﬁts arise from the
more favorable prognosis associated with early-stage
cancers and may prevent treatment for late-stage
breast cancer with possible reductions in treatment
cost. In the 1980s, the demonstration of the efﬁcacy
and effectiveness of mammography with or without
clinical breast examinations in reducing mortality
from breast cancer by 25% to 30% led to the adoption
of guidelines in a number of countries to introduce
routine screening on a population basis [2]. Com-
monly used guidelines recommend the initiation of
mammography screening at the age of 40 to 50 years,
whereas the upper limits are set at 60 to 74 years or
they are left undeﬁned; the suggested screening inter-
vals are 1, 2, or 3 years [2].
The objective of this study was to explore the
cost-effectiveness of population-based mammography
breast cancer screening in Slovenia relative to no
screening, and to choose the most favorable screening
policy with regards to the age eligibility criteria and
screening interval. A probabilistic sensitivity analysis
of the model was undertaken to represent the uncer-
tainty of the model’s parameters.
Methods
Model
A time-dependent Markov model was used to compare
hypothetic populations of women, one followed clini-
cally without screening and the others underwent dif-
ferent screening mammography policies. The structure
of the model, which is presented in Figure 1, is similar
to other models already used in the evaluation of
breast cancer screening programs, such as MISCAN
[3,4] and MICROLIFE [5]. The difference between our
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model and the reported models is in the breast cancer
classiﬁcation approach. While the majority of other
models use tumor size as the classiﬁcation criterion, a
simpliﬁed TNM (Tumor Node Metastasis Classiﬁca-
tion) cancer stage [6] of breast cancers was used in our
model. The model characterizes the natural history of
the disease as having four preclinical stages when
breast cancer can be detected by screening but shows
no clinical symptoms. Approximately 60% of the inva-
sive breast cancers are assumed not to be preceded by
ductal carcinoma in situ (DCIS), which is screen-
detectable and from which a 65% progression to inva-
sive cancer is assumed [7]. The invasive stages are
deﬁned as follows. In the localized stage of breast
cancer, neither regional node involvement nor distant
metastases are found (T1-3 and N0, M0 after TNM
Classiﬁcation). The regional stage includes tumors
classiﬁed as T3 and T4 and/or regional node
metastases (N1), if no metastases in distant lymph
nodes or organs (M0) are found. The disease with
metastases in distant nodes or organs is classiﬁed as
distant stage (M1) [1].
The transitions to clinically diagnosed local,
regional, and distant states are governed by the rate of
the incidence, clinical-stage distribution data, and
sojourn time. In the case of early detection by screen-
ing, the women enter the corresponding screen-
detected DCIS, local, regional, or distant states. The
state “false positives” refers to women with positive
screening examination in whom no breast cancer is
found at further invasive assessment. The two absorb-
ing end-states of the model are death from breast
cancer and death from other causes.
The cohort simulation approach with a cycle length
of 1 week was used for running the Markov model
[8,9], which was developed with the SAS System for
Windows Release 8.02 (SAS Institute Inc., Cary, NC,
USA) [10]. The cycle length of 1 week was chosen to
enable the modeling of the sojourn times and treat-
ment durations with sufﬁcient precision. Breast cancer
incidence, mammography sensitivity, mortality, and
breast cancer relative survival were modeled as time-
dependent transition probabilities.
The perspective for the evaluation was that of
health-care sector and the time horizon covered the full
lifetime of the patients from age 40 years onward. A
discount rate of 3% for costs and effects was applied to
the analyses, in accordance with recommendations
from the Panel on Cost Effectiveness in Health and
Medicine [11]. All costs are expressed in 2004 Euro-
pean euros. Throughout the modeling process, the
principles of good practice for decision analytic mod-
eling in health-care evaluation were followed, as pro-
posed by the ISPOR Task Force on Good Research
Practices-Modeling Studies [12].
Data
All data regarding age-dependent cancer incidence,
clinical-stage distribution, treatments, and survival
were obtained from the Cancer Registry of Slovenia [1].
Because of the introduction of preventive mammogra-
phy examinations (though unorganized) in the early
1990s and consequently the slight shift of clinical-stage
distribution toward the earlier stages of breast cancer,
the database for the time period of 1980–1990was used
for estimating a clinical-stage distribution of breast
cancer. In that period, 41% of breast cancers were
detected in the local stage, 47% in the regional stage,
and the remaining 12% in the distant stage. The data-
base for the period 1999–2001 was used for the estima-
tion of age-dependent incidence. The incidence in this
period is slightly higher than it was in the period
1980–1990; here the assumption was made that the
effect of unorganized screening on higher incidence is
negligible in respect to the effect of higher risk factors in
recent years, which are consequences of less healthy
lifestyle, lower fertility rates, lower average number of
children, higher age at ﬁrst birth, and higher awareness
of the disease [13].
The survival of women with preclinical stages of
breast cancer, of women with screen-detected DCIS,
and of women with false positive results was assumed
to be equal to the survival of women with no breast
cancer. Although this assumption is obvious for
women with false positive results, the choice for the
same assumption in the other two women groups
Figure 1 Structure of the model for breast
cancer screening with the possible courses of
the disease. The dashed lines correspond to
transitions possible only by screening policies.
The state “death from other causes” which can
be attained from all other states is not shown.
DCIS, ductal carcinoma in situ.
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needs further comment. It was reported that opera-
tional removal of DCIS cures at least 98% of lesions
[14] and that the 5-year mortality because of DCIS is
1% [6], which justiﬁes this assumption also for screen-
detected DCIS. The determination of survival of
women with preclinical stages of breast cancer is quite
problematical if not impossible. One possible way to
justify the assumption is by comparing the number of
women that died because of the breast cancer and the
number of women in which the breast cancer was
registered only on the death certiﬁcate. The number of
women, in which breast cancer was registered only on
a death certiﬁcate represents only approximately 1%
to 2% of incidence of breast cancer and only 2% to
4% of deaths because of breast cancer [1]. The
assumption is further justiﬁed by the fact that the
durations of the preclinical stages are quite short when
compared to the durations in the clinical stages.
Stage-speciﬁc relative mortality from breast cancer
(i.e., the proportion of women that die because of
breast cancer after speciﬁc period) was obtained in the
following manner. A relative 1–7 years survival of
breast cancer patients (i.e., the proportion of women
with breast cancer alive after speciﬁc period) diag-
nosed in the period 1991–1995 was subtracted from
the relative survival of the general population (i.e., the
proportion of women alive after speciﬁc period) in
corresponding age groups. Because the obtained rela-
tive stage-speciﬁc mortality was quite similar among
different ages at diagnosis, it was assumed to be inde-
pendent of age at diagnosis.
Various patterns of stage-speciﬁc treatments were
taken from the Cancer Registry of Slovenia for the
same groups of women that were included in the rela-
tive survival calculation, to properly estimate the effect
of treatment on survival. Treatments consisted of four
basic interventions: surgery, hormonal therapy, radio-
therapy, and chemotherapy. For screen-detected DCIS,
surgery with no further treatment was presumed [14].
One of the key assumptions of the screening, and
hence of this model, is that mammography makes it
possible to capture a sizable amount of cancer cases
that would otherwise have gone undetected until the
appearance of clinical symptoms. The model thereby
needs to incorporate an estimate of sojourn time, that
is, the period when the cancer is screen-detectable but
shows no clinical symptoms. We assumed a value of 3
to 7 years with a mean of 5 years [8,15] for DCIS and
a value of 2 to 3 years with a mean of 2.5 years
[16–18] for invasive carcinoma in preclinical local
stage. The sojourn time in preclinical regional and in
preclinical distant states was estimated from the
approximate growth rates of tumors. Approximately
one half of the breast cancers in the Cancer Registry of
Slovenia have a deﬁned TNM stage from which
approximate tumor sizes were calculated for local,
regional, and distant carcinomas. Then the cancer
cells’ doubling times from 60 to 180 days were pre-
sumed to obtain the ranges for a sojourn time of 0.36
to 1.08 years and 0.35 to 1.04 years for regional and
distant stages, respectively; this method was adopted
from Michaelson et al. [19] and Kopans et al. [20].
The assumed sensitivity of the mammography is
86.7% for ages between 40 and 49 years, 93.6% for
ages between 50 and 59 years, 94.1% for ages between
60 and 69 years, and 91.2% for ages 70 years and
older [21]. Based on the results from mass screening in
other countries, a reasonable estimate of the atten-
dance is 75% [22] and the estimate of the recall rate
is 7% [22,23]. About 20% of the women who are
recalled for additional diagnostic procedures undergo
invasive diagnostic procedures such as ﬁne-needle
aspiration and surgical biopsy. The remaining 80%
undergo noninvasive imaging (further mammography,
ultrasound) and clinical examination [22,23]. Diag-
nostic procedures for clinically detected breast cancers
include noninvasive (mammography, ultrasound, clini-
cal examination) and invasive techniques (ﬁne-needle
aspiration, surgical biopsy).
The costs for mammography examination, the costs
for diagnostic interventions for clinically detected
breast cancer, the costs for invasive and noninvasive
diagnostics at recall, and the costs for treatment inter-
ventions were obtained from the Institute of Oncology
Ljubljana [1].
In order to capture the difference in mortality and
morbidity due to screening, health improvement
was measured in quality-adjusted life-years (QALYs).
QALYs for treatment and the corresponding durations
of treatments were obtained from the literature [24].
The quality of life for DCIS, local and regional breast
cancers after treatment was weighted according to the
treatment interventions. The quality of life for distant
cancer was weighted with 0.515 [25].
The quality of life for women with false positive
result was also reduced according to the diagnostic
duration and QALY weight [24]. In the case of death
from breast cancer, a terminal illness lasting 1 month
with QALY weight of 0.288 was taken into account
[24].
Screening Policies
Different screening policies were considered with
respect to the following eligibility criteria: age at the
beginning of the screening, age at the end of the screen-
ing, and the interval between two screenings. All
possible combinations of starting ages 40, 45 and
55 years, ending ages 65, 70, 75 and 80 years, and
screening intervals of 1, 2 and 3 years were considered,
thus giving 36 different screening policies, listed in
Table 1.
Currently, only opportunistic screening activity
takes place in Slovenia. Because there is no register of
the women that underwent such screening, the extent
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of screening would be difﬁcult to estimate suitably.
Therefore, the present situation was omitted from the
analysis and the “null option” chosen for screening
policies was the no-screen option.
Deterministic Cost-Effectiveness Analysis
The cost-effectiveness model for the evaluation of
breast cancer screening was built in several phases. The
model was carefully tested in each phase to ensure that
the mathematical calculations were accurate and con-
sistent with the speciﬁcation of the model (internal
validity of the model). First, a deterministic model for
a cohort without screening was built and calibrated
with the breast cancer incidence data and general sur-
vival. Then, the model was upgraded to include the
screening policies and ﬁnally, the costs and effects in
terms of QALY were incorporated in the model. The
cross validation of the model was carried out with the
published results from screening programs in other
countries. A deterministic evaluation of the model with
the input parameters at their baseline values was
performed and incremental cost-effectiveness ratios
(ICERs) were calculated among nondominated alter-
natives. Additionally, simple one-way sensitivity analy-
sis was performed on all model parameters to test the
robustness of the results [26]. For each of the 82
univariate sensitivity analysis calculations (41 with
parameters on their upper limit and 41 with param-
eters on their lower limit), an efﬁciency frontier with
corresponding ICER was determined thus representing
the impact of parameter value change on the selection
of the optimal policy.
Probabilistic Sensitivity Analysis
Probability distributions were deﬁned for all the model
parameters except for breast cancer incidence and the
cost of mammography examination, as the incidence
of breast cancer has been quite constant in recent years
and the cost of mammography examination is ﬁxed.
Beta distributions were ﬁtted using the method of
moments [27] with mean and standard error drawn
from the literature to represent the uncertainties sur-
rounding probabilities (attendance, recall rate, propor-
tion of invasive diagnostics, sensitivities, clinical-stage
distribution, and progression from DCIS) and QALYs.
A negative exponential function was ﬁtted to stage-
speciﬁc breast cancer relative mortality, and ﬁtted
parameter’s distributions were used to describe the
distributions of relative mortality at speciﬁc times after
the diagnosis. In order to gain distributions of costs for
chemotherapy, hormonal therapy, radiotherapy, and
surgery, an approximate number of patients for
various subtypes of each of the four treatment inter-
ventions (i.e., various types of chemotherapy, hor-
monal therapy, radiotherapy, and surgery) along with
treatment costs were obtained from the Institute of
Oncology Ljubljana. Log-normal distributions were
ﬁtted to different treatment costs and, in a similar
manner, log-normal distributions were ﬁtted to costs
for invasive and noninvasive diagnostic examinations
and for examinations after clinically detected breast
cancer. Finally, a log-normal distribution was assumed
for sojourn times to assure that generated times were
all positive.
The net beneﬁt framework was used for analyzing
the results from probabilistic sensitivity analysis to
derive cost-effectiveness acceptability curves (CEACs)
for each screening policy at different values of willing-
ness to pay per QALY (l) [28,29]. The policies with
the highest expected net beneﬁts (i.e., the policies of
choice) at different l’s were plotted on CEACs in the
form of cost-effectiveness acceptability frontier [30].
Results and Discussion
Deterministic Analysis
During the building phase of the model, the calibration
was performed with the observed breast cancer inci-
dence and general population survival of women.
There was a reasonably good ﬁt of the model’s inci-
dence to the actual data. A good ﬁt was obtained for
the complete life table of Slovenian women as well
(data not shown). Because there is currently no popu-
lation screening program in Slovenia, the results of the
screening part of the model were cross-validated with
the results from pilot and population-based screening
programs in other countries. Mortality reduction from
screening programs is a suitable parameter for com-
parison, even though incidence, treatment, life tables,
and other factors may differ from the modeled Slov-
enian population. In the health insurance plan breast
cancer screening trial, where women aged from 40 to
64 years had been screened, a mortality reduction of
24% has been reported. Our model, assuming the
same screening policy but based on the Slovenian
population, estimates a mortality reduction of 27%.
Table 1 List of screening policies taken into consideration and their labeling in the article
Interval
Screening period
40–65 40–70 40–75 40–80 45–65 45–70 45–75 45–80 50–65 50–70 50–75 50–80
1 1 2 3 4 5 6 7 8 9 10 11 12
2 13 14 15 16 17 18 19 20 21 22 23 24
3 25 26 27 28 29 30 31 32 33 34 35 36
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Analogically, reported mortality reductions in other
studies were compared to the results obtained by our
model: Sweden Two Country Trial—reported 32%
and modeled 34%; Stockholm reported 26% and
modeled 25%; Malmö reported 19% and modeled
29%; Edinburgh reported 21% and modeled 17%
[31]. We found the results agreeable enough to apprise
the model as satisfactory. In addition, a modeled detec-
tion of DCIS was compared to the observed portion of
DCIS in all detected carcinomas to verify the appro-
priateness of the modeled progression to invasive
cancer through DCIS. In the UK screening program,
approximately 18% of all carcinomas were DCIS; our
model, regarding the same screening policy, gives an
estimate of 15%. In The Netherlands the proportion of
DCIS is 13%, while our model gives an estimate of
18% [7].
In order to implement the principles of ICERs and
dominance in economic evaluation of multiple inter-
ventions, mutual exclusivity of those interventions
must be ensured [32,33]. As the screening has an
important effect on mortality, the time horizon for
comparison of costs and effects covered the full life-
time from age 40 years onward, to quantify the differ-
ential impact on life expectancy [34]. The screening
policies noted as, for example, 50 to 75 years with
2-year interval mean that women are followed clini-
cally without screening from ages 40 to 50 years, are
undergoing screening every 2 years from 50 to
75 years, and are again followed clinically until their
death. Hence, the screening policies are mutually
exclusive, as a woman can enter only one screening
program.
Estimates of the differences in costs and differences
in QALYs between the population screened with a
speciﬁc screening policy and the nonscreened popula-
tion are presented in Table 4a in the supplementary
material. The base-case values of the costs and the
QALYs are expressed per one 40-year-old woman. The
cost for a woman from the nonscreened population is
€231 and the effect is 23.0 QALYs. Screening policy 33
(screening from ages 50 to 65 years every 3 years) has
the lowest cost per QALY (€173 for approximately
2 quality-adjusted life-weeks) incrementally to no
screening. The cost-effectiveness results are displayed
graphically in Figure 2. The efﬁciency frontier, repre-
sented by policies 33, 29, 30, 26, 27, 28, and 16, is
outlined as well.
The univariate sensitivity analysis was performed
with upper and lower limits of 95% credibility inter-
vals of parameter distributions and with 1% or 5%
discounting, 10% cancer incidence, and 20% the
cost of mammography examination. The results indi-
cated that the model is quite robust. In virtually all of
the cases (altogether 82 different univariate analyses),
the efﬁciency frontiers consisted of all seven policies
stated in the base-case deterministic analysis. On the
average, the greatest impacts on ICER comparing to
base-case deterministic analysis were observed with
discounting, percent of DCIS progression to invasive
cancer, recall rate, relative mortality in regional stage,
percent of invasive diagnostics, cost of mammography
examination, and percent of invasive cancers preceded
by DCIS.
Probabilistic Sensitivity Analysis
Probabilistic sensitivity analysis of the model was per-
formed with 10,000 Monte Carlo simulations. The
simulation of the cohort without screening and all 36
cohorts with different screening policies took approxi-
Figure 2 Cost-effectiveness plane. Baseline
incremental costs and effects of screening poli-
cies relative to a no-screening on the cost-
effectiveness plane. The efﬁciency frontier
consisting of policies 33, 29, 30, 26, 27, 28, and 16
is outlined.The “no-screening” policy has a cost
of €231 and effect of 23.0 quality-adjusted life-
years (QALYs).
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mately 400 hours on a Pentium IV 3.0 GHz computer.
The results of probabilistic sensitivity analysis can be
presented graphically on a plane showing cost and
effect pairings, but because of the large number of
screening variants, a graphical presentation of all the
screening variants would be very unclear. To indicate
the amount of variation, three screening policies (4,
16, and 33) were compared on a cost-effectiveness
plane. The simulation results revealed quite a large
variation around the base-case analysis. Moreover, a
very high correlation between the costs of different
policies and a very high correlation between the effects
of different policies was observed. This was expected
because all the models are simulated simultaneously
with the same parameters and the models differ only in
the number of screenings and the patients’ ages at
screenings.
A cost-effectiveness acceptability frontier illustrat-
ing the uncertainty over a range of values of l shows
the error probability associated with the optimal strat-
egy at each level of l (Fig. 3). The frontier does not
follow the outer limit of the family of CEAC because
of skewness in the distributions of net beneﬁts. There-
fore, even though the policies 33, 29, and 26 never
have the highest probability of being cost-effective,
they are still the policies of choice at some values of l,
as indicated on Figure 3. Nevertheless, the l ranges at
which these policies are the policies of choice are very
narrow. This is also the case for the policies 30 and 27,
which are policies of choice for ceiling ratios between
€5772 and €7669 per QALY, and €8433 and €13,352
per QALY, respectively. Policy 28 is the policy of
choice at a much wider range of l between €13,352
and €41,815 per QALY, while for ceiling ratios above
€41,815 per QALY, policy 16 is the policy of choice.
No screening is cost-effective at l-values less than
€4307. Consistent with the results of deterministic
analysis, the screening policies with 1-year screening
interval do not feature on CEACs, indicating that they
are never contenders for cost-effectiveness. Among
policies with 2-year screening interval, only the policy
16 is featured on CEAC and is the policy of choice at
high vales of l.
Using the commonly quoted threshold of $50,000
(approximately €38,500) per QALY [35], the optimal
screening policy would be screening women aged from
40 to 80 years every 3 years (screening policy 28). In
fact, this policy remains optimal throughout the wide
range of threshold values between €13,352 and
€41,815 per QALY. The threshold can also be gleaned
from a retrospective analysis of previous resource allo-
cation decisions. Towse and Pritchard analyzed the
ﬁrst 41 decisions made by the UK National Institute
for Clinical Excellence and concluded that the thresh-
olds for likely reimbursement and likely rejection of
therapies were approximately 1.4 and 2.1 times the
gross domestic product (GDP) per capita [36]. Relative
to the Slovenian GDP per capita, these limits in Slov-
enia would be approximately €17,000 and €26,000
per QALY. Applying these thresholds also conﬁrms the
screening policy 28 as the policy of choice.
Negative Aspects of Breast Cancer Screening
The opinion that the screening is an effective way
of reducing the breast cancer mortality is widely
accepted, although not entirely uniﬁed. The opposite
viewpoints are based on the belief that screening causes
more harm than good because of the unnecessary
workup in the population [7]. At 7% recall rate and
20% invasive diagnostics at recall, approximately
1.4% of the screened women will unnecessarily go
through the invasive diagnostic procedures, whereas
(assuming 0.2% yearly incidence and 3-year screening
interval) approximately 0.6%of thewomen population
will be correctly diagnosed with the breast cancer. The
Figure 3 Cost-effectiveness acceptability cur-
ves (CEACs). CEACs (gray lines) with cost-
effectiveness acceptability frontier (CEAF; bold
black line). CEAF illustrates the uncertainty
associated with the optimal policy over a range
of l.CEAF is also presented numerically.CEACs
of other screening policies never reach the 3%
probability of being the most cost-effective.
QALY, quality-adjusted life-year.
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graphical comparison of women in the false positive
state and different cancer states between screened and
nonscreened population is presented in Figure 4.
Although the magnitude of false positives is quite
obvious, there is also clear conformation of the screen-
ing beneﬁts, that is, the decreased breast cancer mortal-
ity and the shift of cancer’s clinical stage distribution
toward earlier stages.
Another issue that has been raised since the initia-
tion of the mammography screening programs is the
possibility of overdiagnosis of the breast cancer, in
particular of the DCIS [7]. Various viewpoints regard-
ing this problem have appeared in the literature
ranging from the opinion that this mainly represents
overdiagnosis and is likely to cause more harm than
beneﬁt, to the position that detection of DCIS is the
ideal target of early detection and that a high rate of
DCIS represents a large number of invasive cancers
avoided [7]. Based on literature estimates of progres-
sion from DCIS to invasive cancers and estimates of
nonprogressive DCIS [7], both aspects of this dilemma
were included in the model.
The downsides of mass screening—overdiagnosis
of the DCIS and the false positives, become more
expressed in screening policies with a shorter interval
between two screenings. As could be expected, more
frequent screening would produce higher beneﬁts, at
of course higher costs. But, one has to consider also
the added negative effects that reduce the incremental
beneﬁts. The model incorporates the negative aspects
of screening by applying the disutility to false positive
state because of invasive diagnostic procedures and by
applying the disutility to “overdiagnosed” part of
screen-detected DCIS state because of unnecessary
treatment. The added negative effect of the screening
because of shortening the screening interval from 3 to
2 years is exceeded by the positive effect in the form of
increased survival. Therefore, the beneﬁts of screening
policies with a 2-year interval are greater than the
beneﬁts of screening policies with a 3-year interval at
the same starting and ending ages. But when the inten-
sity of screening is increased to yearly screenings, the
incremental negative effects prevail over the incremen-
tal beneﬁts from increased survival. This results in the
inability of the yearly screening programs to reach the
effectiveness of equivalent screening policies with a
2-year interval. The comparison of the portions of
women which were diagnosed as false positive during
their life-course for screening policies with 1-, 2-, and
3-year intervals from 40 to 80 years of age was inves-
tigated graphically. Also, the comparison of cumu-
lative breast cancer mortality was compared in
relationship to cumulative breast cancer mortality in
population that is not screened. The cumulative mor-
tality of the screening policy with 1-year interval is
lower than the cumulative mortality for 2-year screen-
ing policy, but the reduction of mortality is much
smaller than that between a 3-year and a 2-year
screening policy. Hence, the positive effect is out-
weighed by a much larger increase of false positive
women.
Nevertheless, by representing the effectiveness
results of the model in the form of (quality-unadjusted)
life-years saved (LYS) and thereby “ignoring” also the
effect of false positives and DCIS overdiagnosis, the
screening policies with a 1-year interval produce
higher effects than the screening policies with a 2-year
interval. The ICER of screening women from 40 to
80 years of age by a 1-year interval (policy 4) over the
same policy with a 2-year interval (policy 16) is
€395,384 per LYS. The ICERs for the policies 28 and
16 are €11,604 and €31,486 per LYS, respectively, and
are lower than the ICERs for cost per QALY. This is
expected, as the negative effects of screening are
ignored in the cost per LYS estimates, which leads
to underestimation of screening’s cost-effectiveness.
Therefore, the inclusion of the QALYs in the model
proves crucial, as the model is then able to capture
the negative and positive effects of screening more
accurately.
Figure 4 Effects of breast cancer screening.
Graphical comparison of the breast cancer
stage distribution, breast cancer cumulative
mortality and portion of women who were
diagnosed as false positive during their life-
course in population that is screened from 40 to
80 years of age by a 3-year interval (black lines)
and the population that is not screened (gray
lines). In the screened population, the percent of
woman in local, regional, and distant stages is the
sum of screen-detected and clinically detected
cancers in corresponding stages.The percentage
of women refers to the total number of women
alive at the age of 40 years. DCIS, ductal carci-
noma in situ.
Cost-Effectiveness of Breast Cancer Screening 145
Comparison with Other Economic Evaluations
As already mentioned, numerous studies on the
economic evaluation of breast cancer screening were
performed. Although the majority of economic evalu-
ations are cost-effectiveness analyses, most of them do
not adhere to basic economic evaluation principles,
which make them difﬁcult to compare. Additionally,
because of the lack of standardization among the
studies, a wide range of results can be found across
breast cancer screening studies [37]. Published esti-
mates of the screening cost per life-year gained vary
from $2844 to $114,300 [38]. Therefore, a suitable
comparison can only be made with similar models,
such as MISCAN [3,4]. De Koning et al. estimated the
cost gained for various screening policies in The Neth-
erlands from €2620 to €4482 per QALY [39]. For the
same policies, our model gives estimates of the cost
gained from €4560 to €7368 per QALY, which is rea-
sonably comparable.
Model Limitations
As with all modeling studies, a number of limitations
of the present study are noticeable. First, it is difﬁcult
to model a very heterogenic disease, such as breast
cancer. Therefore, the choice of appropriate health
states must be considered with great care to conve-
niently capture the progression of breast cancer. We
chose a simpliﬁed TNM stage of breast cancer as the
classiﬁcation criterion of health stages and sacriﬁced
comparability with other studies to model the Slov-
enian population of women as closely as possible.
Moreover, because of the disease characteristics, where
the effects of treatment are not observable in a short
period, the effect of current treatment cannot be esti-
mated precisely. In the model, treatment options for
women diagnosed with breast cancer from 1991 to
1995 were used to capture the 7-year mortality from
breast cancer. It is anticipated that because of improve-
ments in breast cancer treatment (new drugs, better
surgery techniques, guidelines, etc.), better survival is
expected from present treatment options. Neverthe-
less, we believe that observed stage-speciﬁc mortality
for “old” treatments captures the mortality reduction
of breast cancer screening more adequately than just
the assumed value (i.e., of 25–30%) that most of the
other studies use.
Questions also arise about applicability of the
model inputs based on data obtained from foreign
countries. As some factors like attendance, recall, and
portion of invasive diagnostics on recall can be
country-speciﬁc [22,23], great care was taken in esti-
mation of those model inputs. Also, as the prediction
of those parameters is quite uncertain, distributions
with relatively large ranges were applied to those input
parameters (i.e., 95% conﬁdence intervals for atten-
dance were 60–87%, for recall 1–17%, and for inva-
sive diagnostics 5–43%) to implement the lack of
knowledge about those parameters. Furthermore,
since this is a country-speciﬁc economic evaluation,
the transferability of results and conclusions to other
countries is questionable. This problem, or more
appropriately this limitation, is solved by program
characteristics that enable easy incorporation of
country-speciﬁc breast cancer incidence, life tables,
costs, survival, and other inputs. This feature also
allows us to adopt the model to new evidence as it
becomes available thus reducing the degree of uncer-
tainty in model inputs and consequently in model
results.
Further limitation of the model is also the choice of
no-screening as the null option. Only opportunistic
screening activity goes on in Slovenia in accordance
with the instructions for preventive health care, which
state that women aged 50 years and older are liable for
monographic examination every 2 years. Since the
extent of the opportunistic screening in Slovenia could
not be presently estimated, the ICER for present situ-
ation to no-screening cannot be calculated. But as we
have shown that, for example, the screening from ages
50 to 70 years every 2 years is cost-ineffective, the
screening policies of choice in our analysis can only be
more cost-effective when compared to the present situ-
ation. Therefore, the results of our analysis are most
probably overestimates of the current situation in Slo-
venia. The extent of this overestimation is unfortu-
nately not known.
Conclusions
In the present cost-effectiveness analysis, the question
regarding the breast cancer screening in Slovenia was
addressed. It was shown that a 1-year screening inter-
val in population breast cancer screening would
produce fewer beneﬁts at higher costs than less inten-
sive screening and that screening policies with a 2-year
interval would be cost-effective only at high values of
society’s willingness to pay per QALY. This can be
attributed to the increased costs and decreased beneﬁts
because of false positives and DCIS overdiagnosis. But
these two negative aspects of screening are prevailed in
a 3-year interval screening policies by the reduced
breast cancer mortality and by the shift of the breast
cancer stages toward earlier stages. Therefore, based
on commonly quoted thresholds of society’s willing-
ness to pay per QALY, the policy of choice for breast
cancer screening in the Slovenian population would be
screening women aged from 40 to 80 years every
3 years. With this policy, the optimal ratio between the
positive and the negative effects of breast cancer
screening per invested costs is obtained.
To access supplementary material for this article, please
go to: http://www.ispor.org/publications/value/
ViHsupplementary.asp
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